MLYS · Mineralys Therapeutics, Inc. · Webcasts, Transcripts & Audio
$15.60
+0.05 (+0.32%)
At close · Nov 3
Return incl. dividend (before tax)
Q2 2026 earnings call transcript
Market Cap
$1.61B
Shares
88.41M
Volume · Nov 2
4.59M
Avg daily vol (3M)
1.33M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Mineralys Therapeutics, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Mineralys Therapeutics, Inc. (MLYS), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-04
Mineralys Therapeutics, Inc. (MLYS) Q3 2026 Earnings Call
Scheduled
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-09
Mineralys Therapeutics, Inc. (MLYS) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-11
Mineralys Therapeutics, Inc. (MLYS) Q2 2026 Earnings Call Transcript
Confident tone
Pricing strategy
CKD and cardiorenal opportunity beyond hypertension
Commercial launch readiness
Diluted EPS
$-2.85
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
Mineralys Therapeutics, Inc. (MLYS) June 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-03
Mineralys Therapeutics, Inc. (MLYS) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Annual General Meeting
Investor event
2026-05-21
Mineralys Therapeutics, Inc. (MLYS) May 21, 2026 Annual General Meeting Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-12
Mineralys Therapeutics, Inc. (MLYS) May 12, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-06
Mineralys Therapeutics, Inc. (MLYS) Q1 2026 Earnings Call Transcript
Confident tone
Unmet need in resistant hypertension
Partnering and business development
Clinical data package and differentiation
Diluted EPS
$-0.47
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-12
Mineralys Therapeutics, Inc. (MLYS) Q4 2025 Earnings Call Transcript
Confident tone
FDA NDA acceptance and PDUFA date
EXPLORER-OSA trial results (mixed)
Life-cycle and indication expansion
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-10
Mineralys Therapeutics, Inc. (MLYS) Q3 2025 Earnings Call Transcript
Confident tone
Lorundrostat clinical efficacy in hypertension
Label-expansion indications (CKD, OSA, heart failure)
NDA submission progress
Diluted EPS
$-0.52
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Mineralys Therapeutics, Inc. (MLYS) Q2 2025 Earnings Call Transcript
Confident tone
Lorundrostat pivotal data and differentiation
Lifecycle extension in CKD and OSA
Pre-commercial readiness and partnering
Diluted EPS
$-0.66
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
Mineralys Therapeutics, Inc. (MLYS) Q1 2025 Earnings Call Transcript
Confident tone
Pivotal Phase 3 Trial Results (Launch-HTN and Advance-HTN)
Commercial Opportunity and Physician Interest
Explore-CKD Trial (Chronic Kidney Disease)
Diluted EPS
$-0.79
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-12
Mineralys Therapeutics, Inc. (MLYS) Q4 2024 Earnings Call Transcript
Confident tone
Lorundrostat Drug Profile
Pivotal Trial Readouts (Advance-HTN and Launch-HTN)
Explore-CKD Phase II Trial
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Mineralys Therapeutics, Inc. (MLYS) Q3 2024 Earnings Call Transcript
Confident tone
Pivotal Advance-HTN trial
Pivotal Launch-HTN trial
Explore-CKD Phase II trial
Diluted EPS
$-1.13
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
Mineralys Therapeutics, Inc. (MLYS) Q2 2024 Earnings Call Transcript
Confident tone
Lorundrostat Pivotal Program / Hypertension
FDA Alignment & Trial Design
Competitive Landscape (MRAs vs ASI)
Diluted EPS
$-0.83
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Mineralys Therapeutics, Inc. (MLYS) Q1 2024 Earnings Call Transcript
Confident tone
Pivotal Hypertension Trials
Targeted/Precision Medicine Strategy
CKD Proof-of-Concept Trial
Diluted EPS
$-0.70
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-21
Mineralys Therapeutics, Inc. (MLYS) Q4 2023 Earnings Call Transcript
Confident tone
Pivotal hypertension program (Advance-HTN / Launch-HTN)
Explore-CKD Phase 2 trial
Obesity / GLP-1 interplay and differentiation
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Mineralys Therapeutics, Inc. (MLYS) Q3 2023 Earnings Call Transcript
Diluted EPS
$-0.57
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-07
Mineralys Therapeutics, Inc. (MLYS) Q2 2023 Earnings Call Transcript
Diluted EPS
$-0.31
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-15
Mineralys Therapeutics, Inc. (MLYS) Q1 2023 Earnings Call
Diluted EPS
$-0.51
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-15
Mineralys Therapeutics, Inc. (MLYS) Q4 2022 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Showing 1–21 of 21 webcasts
Key facts
CIK
1933414
CUSIP
603170101
13F (30d)
37 filings
37 filers
Visit website
Investor relations